Variational AI, founded in 2019, applies generative AI to accelerate small molecule drug discovery for the pharmaceutical and biotechnology sectors. The company develops foundation models that generate novel, synthesizable chemical compounds, optimizing across multiple parameters simultaneously to streamline the traditionally lengthy process of identifying drug candidates.
The firm's primary product, Enki, is a generative AI foundation model designed for de novo compound generation. It optimizes across more than 50 parameters and aims to reduce the timeline for delivering lead candidates from years to weeks.
The company's technical work spans generative AI, machine learning, chemistry, and drug discovery. Its founding team includes researchers with backgrounds from institutions such as Google, Microsoft, MIT, Caltech, and D-Wave Quantum.
